Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Message for Thtx
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by ANALIAS00on Sep 02, 2021 9:23am
124 Views
Post# 33800003

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Message for Thtx

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Message for Thtx Normally those windows are available to less interesting subjet. It is like products on a shelf in a store, the space right in front of your eyes will sell more so cie will pay more to get that perfect spot. So either THTX was not willing to pay the price for a better spot or the organizers do not beleive THTX presentation is interesting enought compare to other cie's presentation. At noon most people on site will prefer eating a good free lunch with peers and those remote will take a break. :o(
SPCEO1 wrote: Does anyone know a reason why they would schedule this event at Noon? I can't see an advantage to having it then, but perhaps I am missing something.

scarlet1967 wrote: For instance LSA emailed folks on their list while ago and today the below, now why no PR from company or posts re the event on the social media platforms?
freaking frustrating 
https://www.linkedin.com/posts/lifesci-advisors_please-join-us-on-monday-september-13th-activity-6838833018837241856-mAYo




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities